Start with the news release Diagnostics by mass spectrometry and microdosing from Vitalea Science, which we summarised at the time by saying "Vitalea Science announces grant award for phase-1 development of a diagnostic test utilizing accelerator mass spectrometry and microdosing technologies". Several months prior to that, we featured the news release Xceleron leads EU microdose partnership programme from Xceleron: "Xceleron, the bioanalytical CRO specialising in accelerator mass spectrometry (AMS) services, announces that it has been asked to lead the European Union Microdose AMS partnership programme (Eumapp)".
 
In October 2005, we covered the news from Vitalea Science - take a look at Accelerating technology for HIV drug testing which says: "Microdosing approach, where harmlessly small quantities of a new medicine are studied directly in humans to circumvent years of animal testing, moves forward with publication of AZT study results".
 
Take a look also at the news release from Vitalea Science, First human microdosing study of anti-HIV compound, as well as Human microdosing points the way forward from Pharmaceutical Profiles, and Small doses mean big business from Pharmaceutical Profiles.